We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Molecular Influenza and Streptococcus Tests Get FDA Clearance

By LabMedica International staff writers
Posted on 07 Nov 2018
Each year, a combination of influenza A and B virus strains circulate within the USA. More...
The burden of influenza in the USA is currently estimated to be 9 to 36 million cases per year. The disease and its complications cause as many as 140,000 to 710,000 hospitalizations and 12,000 to 56,000 deaths annually. Influenza also poses a significant economic burden including medical care expenses and loss of productivity.

Pharyngitis, or inflammation of the pharynx causing sore throat, is diagnosed in 11 million patients in USA emergency departments and ambulatory settings annually. Group A Streptococcus (GAS) is the most common bacterial cause of acute pharyngitis, accounting for 15% to 30% of cases in children and 5% to 20% of cases in adults. GAS is easily and frequently spread among families and other close contacts via respiratory secretions, and infection peaks in the late winter and early spring.

The US Food and Drug Administration (Silver Springs, MS, USA) have cleared next-generation Influenza A & B 2 and Strep A 2 molecular assays for point-of-care testing. The new assays enable fast time-to-results for molecular influenza A & B and Strep A testing at the point of care. Both assays have also been granted CLIA waivers and are available for use with the Abbott ID Now platform, formerly the Alere I, a rapid, instrument-based, isothermal nucleic acid amplification system for the qualitative detection of infectious diseases.

The Influenza A & B 2 assay provides point-of-care molecular detection and differentiation of influenza A and B virus in 13 minutes or less, and it calls out positive results in five minutes. The assay enables room temperature storage of all test components, which simplifies and streamlines test ordering and storage. The Strep A 2 test provides molecular detection of group A Streptococcus bacterial nucleic acid, the primary cause of bacterial pharyngitis, or sore throat, in six minutes or less, and it calls out positive results in two minutes. Culture confirmation is not required for negative results.

Gregory Berry, PhD, D(ABMM), director of molecular diagnostics at Northwell Health Laboratories (Lake Success, NY, USA), said, "Rapid testing may also help reduce improper antibiotic usage, which can occur when treatment is based exclusively on a patient's symptoms, and contributes to antibiotic resistance.”

Related Links:
US Food and Drug Administration
Northwell Health Laboratories


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
Automated Microscope
dIFine
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.